ARDELYX, INC. Gains (Losses) on Restructuring of Debt
ARDELYX, INC. (ARDX) reported Gains (Losses) on Restructuring of Debt of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnRestructuringOfDebt · last filed 2023-05-03
- ARDELYX, INC. gains (losses) on restructuring of debt for the quarter ending 2023-03-31 was $0.00.
- ARDELYX, INC. gains (losses) on restructuring of debt for the quarter ending 2022-12-31 was $0.00.
- ARDELYX, INC. gains (losses) on restructuring of debt for the quarter ending 2022-09-30 was $0.00.
- ARDELYX, INC. gains (losses) on restructuring of debt for the quarter ending 2022-06-30 was $0.00.
- ARDELYX, INC. gains (losses) on restructuring of debt for fiscal 2022 was -$102.00K.
- ARDELYX, INC. gains (losses) on restructuring of debt for fiscal 2021 was $0.00.
- ARDELYX, INC. gains (losses) on restructuring of debt for fiscal 2020 was $0.00.
| Period end | Gains (Losses) on Restructuring of Debt 3 month | Gains (Losses) on Restructuring of Debt 6 month | Gains (Losses) on Restructuring of Debt 9 month | Gains (Losses) on Restructuring of Debt 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2023-05-03 | $0.00 derived: sum of 3 quarters · filed 2023-05-03 | $0.00 derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | -$102.00K 10-K · filed 2023-03-02 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | -$102.00K 10-Q · filed 2022-11-03 | -$102.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$102.00K 10-Q · filed 2022-08-04 | -$102.00K derived: sum of 3 quarters · filed 2023-05-03 | -$102.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2022-03-31 | -$102.00K 10-Q · filed 2023-05-03 | -$102.00K derived: sum of 2 quarters · filed 2023-05-03 | -$102.00K derived: sum of 3 quarters · filed 2023-05-03 | -$102.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $0.00 derived: sum of 2 quarters · filed 2023-03-02 | $0.00 derived: sum of 3 quarters · filed 2023-03-02 | $0.00 10-K · filed 2023-03-02 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |